173 related articles for article (PubMed ID: 37438214)
1. EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker.
Gautam N; Kaur S; Kashyap S
Arch Med Res; 2023 Jul; 54(5):102852. PubMed ID: 37438214
[TBL] [Abstract][Full Text] [Related]
2. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
3. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
Reijm EA; Timmermans AM; Look MP; Meijer-van Gelder ME; Stobbe CK; van Deurzen CHM; Martens JWM; Sleijfer S; Foekens JA; Berns PMJJ; Jansen MPHM
Ann Oncol; 2014 Nov; 25(11):2185-2190. PubMed ID: 25193989
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
5. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
6. The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.
Tao R; Chen Z; Wu P; Liu C; Peng Y; Zhao W; Hu C; Feng J
Tumour Biol; 2015 Dec; 36(12):9849-55. PubMed ID: 26162541
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
[TBL] [Abstract][Full Text] [Related]
8. Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology.
Liu LC; Chien YC; Wu GW; Hua CH; Tsai IC; Hung CC; Wu TK; Pan YR; Yang SF; Yu YL
Int J Med Sci; 2022; 19(6):1023-1028. PubMed ID: 35813302
[TBL] [Abstract][Full Text] [Related]
9. EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population.
Zhou Y; Du WD; Wu Q; Liu Y; Chen G; Ruan J; Xu S; Yang F; Zhou FS; Tang XF; Tang HY; Zuo XB; Zhang FY; Sun LD; Zhang XJ
Mol Carcinog; 2014 Aug; 53(8):589-97. PubMed ID: 22228224
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
[TBL] [Abstract][Full Text] [Related]
11. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.
Yu YL; Su KJ; Hsieh MJ; Wang SS; Wang PH; Weng WC; Yang SF
PLoS One; 2014; 9(4):e93635. PubMed ID: 24691023
[TBL] [Abstract][Full Text] [Related]
12. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
[TBL] [Abstract][Full Text] [Related]
13. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.
Yu YL; Su KJ; Hsieh YH; Lee HL; Chen TY; Hsiao PC; Yang SF
PLoS One; 2013; 8(9):e74870. PubMed ID: 24040354
[TBL] [Abstract][Full Text] [Related]
14. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
15. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
16. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
17. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
Belpinati F; Malerba G; Dal Toè M; Ceccuzzi L; Rodolfo M; Poli A; Turco A; Vergani E; Sangalli A; Gomez-Lira M
Exp Dermatol; 2020 Oct; 29(10):980-986. PubMed ID: 32748461
[TBL] [Abstract][Full Text] [Related]
19. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
[TBL] [Abstract][Full Text] [Related]
20. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
